Author: Elliogen

  • Navigating the French Healthcare System: Understanding Government Bodies and Their Roles

    Navigating the French Healthcare System: Understanding Government Bodies and Their Roles

    France’s healthcare system is renowned for its efficiency and effectiveness, providing high-quality medical care to its citizens. This success is largely attributed to the various government bodies that oversee different aspects of healthcare. Understanding the roles and connections of these bodies is crucial for anyone looking to engage with the French healthcare sector. Let’s take…

  • Early Access Program in France

    Early Access Program in France

    In the heart of France’s innovative healthcare landscape, the Early Access Program (EAP), locally known as “Accès Précoce” (formerly “Autorisation Temporaire d’Utilisation” or ATU), stands as a beacon of hope. This remarkable program bridges the gap between urgent patient needs and medical innovation, offering a lifeline to those facing serious or rare diseases with no…

  • Centralised Procedure in Europe: A Primer for US-Based Pharmaceutical Companies

    Centralised Procedure in Europe: A Primer for US-Based Pharmaceutical Companies

    The pharmaceutical industry is a vast landscape of innovation, regulatory standards, and international processes. As US-based pharmaceutical companies expand their operations and look to tap into the European market, it’s imperative to understand the regulatory environment. One of the most pivotal regulatory pathways for gaining market access in Europe is the Centralised Procedure. Here’s a…

  • Infographic – French Pharmaceutical Market

    Infographic – French Pharmaceutical Market

    Have a look at our infographic on how the French Pharmaceutical market works, the size and some other valuable information

  • Navigating the World of Off-Patent Products: Your Guide to Success

    Navigating the World of Off-Patent Products: Your Guide to Success

    Are you considering venturing into the realm of off-patent pharmaceutical products? This market segment offers immense opportunities for growth and diversification of your product portfolio. However, navigating the complexities from initial discussions to the final stages of acquisition and transfer can be daunting. That’s where our expertise comes into play. Our Comprehensive Approach At our…

  • What affects the supply of medicine in the Pharmaceutical Industry?

    What affects the supply of medicine in the Pharmaceutical Industry?

    What affects the supply of medicine in the Pharmaceutical Industry? One of the main reasons that prescription drug costs make headlines is because of the actors in the supply chain. This study aims to investigate the reasons for the lack of medicines and their effects on the supply of medicines. We could learn more about…

  • Enhancing Patient Experience: A Strategic Imperative for Pharmaceutical Companies

    Enhancing Patient Experience: A Strategic Imperative for Pharmaceutical Companies

    In the dynamic world of healthcare, understanding the patient journey—often termed as ‘care flow’—is a crucial aspect that pharmaceutical companies cannot afford to overlook. This journey encompasses a comprehensive visual map of care events, charting the course from the onset of symptoms to the achievement of a cure. Traditionally, the focus within the pharmaceutical industry…

  • Exploring the Unique French Retail Pharmacy Market

    Exploring the Unique French Retail Pharmacy Market

    The retail pharmacy landscape in France presents a fascinating study in uniqueness, distinctly different from its European counterparts. This article delves into the nuances of this market, highlighting what sets French retail pharmacies apart. A Market of Singular Ownership In a striking contrast to many European countries, France does not have pharmacy chains. This means…

  • Pharma on social media, good idea?

    Pharma on social media, good idea?

    Due to strict regulations, numerous pharmaceutical companies are very cautious about their presence on the social medias, therefore they often prefer not to play in this game rather than taking any risks. While 50 largest drugmakers worldwide, only half are involved on social media and only 10 of them use all three of the largest…